-
The new version of the tertiary hospital review pays close attention to illegal procurement and malicious insurance fraud
Time of Update: 2022-12-30
Since the beginning of this year, the Central Commission for Discipline Inspection and the State Supervision Commission have repeatedly intensively reported on medical anti-corruption, drug kickbacks and other issues, and while medical representatives, pharmaceutical companies and other relevant personnel have been brought out, many "number one" in third-class hospitals have also fallen one after another.
-
Photodynamic drugs antitumor stem cell and ribosomal inhibition
Time of Update: 2022-10-02
Ribosomes in each mammal copy number is tens of millions, accounting for about 10% of the total copy number of proteins in the cell, 85% of the total RNA, consuming more than 50% of the total ATP of
-
You need to know at least these 6 things about allopurinol
Time of Update: 2022-09-21
Domestic and foreign guidelines recommend allopurinol as a first-line drug for the treatment of uric acid lowering in patients with hyperuricemia and gout.
Domestic and foreign guidelines recommend allopurinol as a first-line drug for the treatment of uric acid lowering in patients with hyperuricemia and gout.
-
Importance of pharmaceutical packaging materials and standardization of testing
Time of Update: 2022-06-21
Commonly used pharmaceutical packaging materials are paper products, plastics, glass, metal, wood, review materials, rubber products, etc.
*Guidelines for the study of self-stability of plastic and rubber pharmaceutical packaging materials .
-
More than 60% of the courier patients achieved symptom improvement, and two phase 3 clinical results of broad-spectrum antibacterial drugs were positive
Time of Update: 2022-06-07
▎WuXi AppTec Content Team Editor A few days ago, SCYNEXIS announced that its innovative oral antifungal investigational therapy ibrexafungerp has received positive interim results in two Phase 3 clinical trials, continuing to demonstrate ibrexafungerp's potential to treat difficult-to-treat fungal infections in hospital settings .
-
Domestic PD-(L)1 explodes in 2021, and imported drugs face extinction
Time of Update: 2022-01-09
In November of this year, Professor Lu Shun from the Thoracic Hospital of Shanghai Jiaotong University reported at the ESMO Asia conference the interim analysis results of the randomized, double-blind, multicenter phase III study ORIENT-31 (NCT03802240), showing that Sintilizumab is combined Bevacizumab biosimilars and chemotherapy for EGFR-positive locally advanced or metastatic non-squamous NSCLC patients who have progressed through EGFR-TKI treatment have obtained significant and clinically significant PFS prolongation .
-
Junshi Biological Appoints Dr. Virginia Ellen Maher as Vice President of Medical Sciences
Time of Update: 2021-12-09
Maher worked in the US Food and Drug Administration (FDA) for nearly 20 years, serving as a clinical reviewer of the Office of Oncology Products, and a clinical review team of the Office of Cell, Tissue and Gene Therapy of the Center for Biologics Evaluation and Research (CBER) Chief, the clinical review team leader of the Office of Hematology and Tumor Products of the Center for Drug Evaluation and Research (CDER) .
-
Issued by the National Health Commission: Maternal and Child Safety Action Improvement Plan (2021-2025
Time of Update: 2021-10-20
On the basis of continuous improvement of treatment capabilities, all levels of critically ill maternal and neonatal treatment centers must pay close attention to the implementation of scribing and zoning responsibilities, strengthen guidance to lower-level medical institutions, and establish a high-level linkage and efficient consultation and referral mechanism to further smooth The green channel for critically ill referrals will ensure the safety of pregnant women and newborns .
-
The most complete summary of the top ten targets and drugs for precision treatment of pancreatic cancer in 2021
Time of Update: 2021-08-04
The results showed that compared with placebo, olaparib as a maintenance treatment drug can significantly prolong the progression-free survival of patients with metastatic pancreatic cancer (7.
-
Where is the next leap in CAR-T therapy? Cinda Bio and other Chinese companies explore new directions
Time of Update: 2021-03-27
According to the official website of Reindeer Medical, for patients with relapsed/refractory multiple myeloma, high-dose BCMA targeted CAR-T cell therapy may provide better remission, but the adverse events are more serious.
-
Koren has another class of new drugs coming! 15 new heavy-weight products have been approved
Time of Update: 2020-12-23
Form 1:2020 to date, Colum Pharmaceuticals declared clinical 1 new drug source: Minet MED2.0 China Drug Review Database December 14, Colum Pharmaceuticals Holding Subsidiary Sichuan Columbotai Bio with the new drug Class 1 submitted SK337 injection clinical application was accepted by CDE contractor, acceptance number CXSL2000339.
-
The Drug Administration adjusts part of the Sub-Catalog of 6840 In-body Diagnostic Reagents Classification (2013 Edition
Time of Update: 2020-10-31
If renewal is required, the registrar shall apply to the corresponding drug regulatory department for renewal of registration in accordance with the changed category six months before the expiration of the validity period of the medical device registration certificate, and if the renewal registration is granted, the medical device registration certificate shall be issued in accordance with the adjusted product management category.
-
API enterprises will usher in dramatic changes
Time of Update: 2020-10-02
In accordance with the requirements of the ecological protection red line, the bottom line of environmental quality, the use of resources on-line, and the list of access to the ecological environment, reasonable planning of industrial regional layout, gradually improve the level of green development of the main production areas of raw materials and drugs, accelerate the upgrading and transformation of enterprises in environmentally sensitive areas and industrial transfer, environmental air quality non-compliant cities should formulate more stringent access standards.
-
Aiming at the nearly 100 billion CRO market, he used AI to dig deep into real-world research, so that pharmaceutical research and development into the "autonomous driving" era
Time of Update: 2020-08-12
Zhang Hongliang is a master's degree in China Medical University, has 12 years of experience in drug research and development in the clinical research industry, deep understanding of industry pain points, and at the end of 2016 to create remote medical technology, unique path, deep-dive industry pain points, focus on phase IV clinical and post-market large sample size research, through artificial intelligence to solve data collection and processing problems, significantly reduce costs, improve data quality, open the "AI-CRO" era.
-
Over-rated more than 3 drugs cancelled on the network (with list
Time of Update: 2020-07-28
Pharmaceutical Network Monthly , Shaanxi Province, the centralized procurement platform of pharmaceutical equipment recently issued "on the national organization of centralized procurement of drugs an
